Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

PLoS One · 2017 · PMC5576694 · PMID 28854272

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Efficacy of 1 st line and 2 nd line TKI treatments Median PFS on first-line erlotinib or gefitinib TKI treatment in those who turned out to be T790M positive (n = 22) and negative (n = 7) in later biopsies showed a trend to be different, 13.3 months (95% CI., 10–17) and 8.1 months (95% CI., 0–16) respectively (p = 0.06; Fig 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.